Marc Tessier-Lavigne - 07 Jun 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
07 Jun 2021
Net transactions value
-$4,874,248
Form type
4
Filing time
08 Jun 2021, 17:10:48 UTC
Previous filing
04 Jun 2021
Next filing
15 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $707,454 +39,303 +1.5% $18.00 2,583,673 07 Jun 2021 Direct F1
transaction DNLI Common Stock Options Exercise $526,544 +27,830 +1.1% $18.92 2,611,503 07 Jun 2021 Direct F1
transaction DNLI Common Stock Options Exercise $531,278 +27,245 +1% $19.50 2,638,748 07 Jun 2021 Direct F1
transaction DNLI Common Stock Sale $6,589,779 -93,678 -3.6% $70.34 2,545,070 07 Jun 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale $49,744 -700 -0.03% $71.06 2,544,370 07 Jun 2021 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -39,303 -83% $0.000000 7,862 07 Jun 2021 Common Stock 39,303 $18.00 Direct F5
transaction DNLI Stock Option (right to buy) Options Exercise $0 -27,830 -100% $0.000000* 0 07 Jun 2021 Common Stock 27,830 $18.92 Direct F6
transaction DNLI Stock Option (right to buy) Options Exercise $0 -27,245 -100% $0.000000* 0 07 Jun 2021 Common Stock 27,245 $19.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 2,074 restricted stock units.
F2 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F3 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.965 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.02 to $71.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 25% of the shares subject to the option vested on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.
F6 100% of the shares subject to the option were fully vested and exercisable.